Secondary stroke prevention in women

Women's Health

Volumn 7, Issue 3, 2011, Pages 391-397

  Acciarresi, Monica ^a   De Rango, Paola ^b   Pezzella, Francesca Romana ^c   Santalucia, Paola ^d   Amici, Serena ^a   Paciaroni, Maurizio ^a   Mommi, Valeria ^a   Agnelli, Giancarlo ^a   Caso, Valeria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Teaching Hospital SM della Misericordia   (Italy)

^c Stroke Unit   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

antiplatelets; carotid stenosis; secondary prevention; stroke; women

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; COMORBIDITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MYOPATHY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK;

BRAIN ISCHEMIA; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; STENTS; STROKE;

EID: 79957547504     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.20     Document Type: Review

References (50)

1. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 9061, 1269-1276 (1997).
2. Lloyd-Jones D, Adams R, Carnethon M et al.: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 3, 480-486 (2009).
3. Ajayi AA, Mathur R, Halushka PV: Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 11, 2742-2747 (1995).
4. Feuring M, Christ M, Roell A et al.: Alterations in platelet function during the ovarian cycle. Blood Coagul. Fibrinolysis 5, 443-447 (2002).
5. Chiang N, Hurwitz S, Ridker PM et al.: Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 2, e14-e17 (2006).
6. Cavallari LH, Helgason CM, Brace LD et al.: Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann. Pharmacother. 5, 812-817 (2006).
7. Ridker PM, Cook NR, Lee IM et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 13, 1293-1304 (2005). Randomized controlled trial designed for women.
8. Baigent C, Blackwell L, Collins R et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 9678, 1849-1860 (2009).
9. Holroyd-Leduc JM, Kapral MK, Austin PC et al.: Sex differences and similarities in the management and outcome of stroke patients. Stroke 8, 1833-1837 (2000).
10. Glader EL, Stegmayr B, Norrving B et al.: Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 8, 1970-1975 (2003).
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 9038, 1329-1339 (1996).
12. Beinart SC, Kolm P, Veledar E et al.: Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol. 5, 761-769 (2005).
13. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 9281, 527-533 (2001).
14. Saw J, Topol EJ, Steinhubl SR et al.: Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am. J. Cardiol. 5, 623-625 (2004).
15. Fox KA, Mehta SR, Peters R et al.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 10, 1202-1208 (2004).
16. Diener HC, Bogousslavsky J, Brass LM et al.: Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc. Dis. 2-3, 253-261 (2004). Randomized controlled trial to compare the effect between aspirin plus placebo versus aspirin plus clopidogrel.
17. The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet 8572, 1351-1354 (1987).
18. Diener HC, Cunha L, Forbes C et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 1-2, 1-13 (1996).
19. De Schryver EL, Algra A, van Gijn J: Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 8, 2072-2080 (2003).
20. Halkes PH, van Gijn J, Kappelle LJ et al.: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 9523, 1665-1673 (2006). Randomized controlled trial comparing aspirin versus aspirin plusdipiridamole.
21. Lokk J: Dipyridamole-associated headache in stroke patients - interindividual differences? Eur. Neurol. 2, 109-113 (2009).
22. Sacco RL, Diener HC, Yusuf S et al.: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 12, 1238-1251 (2008).
23. Dale KM, Coleman CI, Shah SA et al.: Impact of gender on statin efficacy. Curr. Med. Res. Opin. 3, 565-574 (2007).
24. Amarenco P, Bogousslavsky J, Callahan A 3rd et al.: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 6, 549-559 (2006). First randomized controlled trial for statin in secondary stroke prevention.
25. Bushnell CD, Griffin J, Newby LK et al.: Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke 6, 1427-1431 (2006).
26. Wang TJ, Massaro JM, Levy D et al.: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 8, 1049-1056 (2003).
27. Madias C, Trohman RG: The link between atrial fibrillation and stroke in women. Womens Health (Lond. Engl.) 7(3), (2011).
28. Rothwell PM, Eliasziw M, Gutnikov SA et al.: Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke. Stroke 12, 2855-2861 (2004). Meta-analysis of all randomized controlled trial of carotid surgery focusing on sex differences.
29. Bond R, Rerkasem K, Rothwell PM: Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. Stroke 9, 2290-2301 (2003).
30. Schulz UG, Rothwell PM: Sex differences in carotid bifurcation anatomy and the distribution of atherosclerotic plaque. Stroke 7, 1525-1531 (2001).
31. Farb A, Burke AP, Tang AL et al.: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 7, 1354-1363 (1996).
32. Joakimsen O, Bonaa KH, Stensland-Bugge E et al.: Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: the Tromso Study. Arterioscler. Thromb. Vasc. Biol. 12, 3007-3013 (1999).
33. Hellings WE, Pasterkamp G, Verhoeven BA et al.: Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy. J. Vasc. Surg. 2, 289-296 (2007).
34. Iemolo F, Martiniuk A, Steinman DA et al.: Sex differences in carotid plaque and stenosis. Stroke 2, 477-481 (2004).
35. Taylor DW, Barnett HJ, Haynes RB et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) trial collaborators. Lancet 9171, 2179-2184 (1999).
36. Alamowitch S, Eliasziw M, Barnett HJ: The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke 1, 27-31 (2005)
37. Bond R, Rerkasem K, Cuffe R et al.: A systematic review of the associations between age and sex and the operative risks of carotid endarterectomy. Cerebrovasc. Dis. 2, 69-77 (2005).
38. Kapral MK, Wang H, Austin PC et al.: Sex differences in carotid endarterectomy outcomes: results from the Ontario Carotid Endarterectomy Registry. Stroke 5, 1120-1125 (2003).
39. Hansen F, Mangell P, Sonesson B, et al.: Diameter and compliance in the human common carotid artery - variations with age and sex. Ultrasound Med. Biol. 1, 1-9 (1995).
40. Touze E, Calvet D, Chatellier G et al.: Carotid stenting. Curr. Opin. Neurol. 1, 56-63 (2008).
41. Furie KL, Kasner SE, Adams RJ et al.: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 227-276 (2011). Latest updated guidelines.
42. De Rango P, Parlani G, Caso V et al.: A comparative analysis of the outcomes of carotid stenting and carotid endarterectomy in women. J. Vasc. Surg. 2, 337-344 (2010).
43. Eckstein HH, Ringleb P, Allenberg JR et al.: Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol. 10, 893-902 (2008).
44. Stingele R, Berger J, Alfke K et al.: Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol. 3, 216-222 (2008).
45. Yadav JS, Wholey MH, Kuntz RE et al.: Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 15, 1493-1501 (2004).
46. Mas JL, Chatellier G, Beyssen B et al.: Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N. Engl. J. Med. 16, 1660-1671 (2006). Randomized controlled trial comparing carotid surgery versus stenting.
47. Mas JL, Trinquart L, Leys D et al.: Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol. 10, 885-892 (2008).
48. Ederle J, Dobson J, Featherstone RL et al.: Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 9719, 985-997 (2010). Randomized controlled trial comparing carotid surgery versus stenting.
49. Bonati LH, Dobson J, Algra A et al.: Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 9746, 1062-1073 (2010). Meta-analysis comparing carotid surgery versus stenting.
50. Brott TG, Hobson RW 2nd, Howard G et al.: Stenting versus endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 1, 11-23 (2010).